Your browser is no longer supported. Please, upgrade your browser.
NEW! We've added Bitcoin charts to our Forex section. ×
Settings
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E79.50 EPS (ttm)2.96 Insider Own2.30% Shs Outstand343.12M Perf Week4.38%
Market Cap80.74B Forward P/E15.16 EPS next Y15.52 Insider Trans0.91% Shs Float332.77M Perf Month11.83%
Income1.01B PEG2.91 EPS next Q2.46 Inst Own66.80% Short Float1.62% Perf Quarter16.49%
Sales8.57B P/S9.42 EPS this Y198.90% Inst Trans20.54% Short Ratio2.34 Perf Half Y64.92%
Book/sh19.16 P/B12.28 EPS next Y38.86% ROA3.40% Target Price52.38 Perf Year76.31%
Cash/sh5.43 P/C43.31 EPS next 5Y27.30% ROE18.20% 52W Range106.00 - 238.49 Perf YTD64.43%
Dividend- P/FCF44.97 EPS past 5Y19.20% ROI8.40% 52W High-1.33% Beta0.81
Dividend %- Quick Ratio4.90 Sales past 5Y58.70% Gross Margin73.00% 52W Low121.99% ATR5.60
Employees16800 Current Ratio5.20 Sales Q/Q16.20% Oper. Margin34.80% RSI (14)71.19 Volatility2.32% 2.98%
OptionableYes Debt/Eq4.03 EPS Q/Q400.00% Profit Margin11.80% Rel Volume0.71 Prev Close237.53
ShortableYes LT Debt/Eq4.01 EarningsApr 29 BMO Payout0.00% Avg Volume2.31M Price235.31
Recom3.00 SMA206.32% SMA5011.75% SMA20047.91% Volume2,044,200 Change-0.93%
May-26-15Reiterated RBC Capital Mkts Outperform $249 → $265
Apr-30-15Reiterated UBS Buy $222 → $240
Apr-30-15Reiterated Stifel Buy $230 → $250
Apr-30-15Reiterated RBC Capital Mkts Outperform $239 → $249
Apr-30-15Reiterated Cantor Fitzgerald Buy $222 → $271
Feb-25-15Reiterated CRT Capital Buy $180 → $220
Feb-24-15Reiterated UBS Buy $165 → $222
Feb-24-15Reiterated Stifel Buy $175 → $230
Feb-12-15Reiterated RBC Capital Mkts Outperform $188 → $191
Feb-09-15Initiated Barclays Overweight $200
Jan-09-15Reiterated UBS Buy $155 → $165
Feb-28-14Reiterated UBS Buy $141 → $170
Feb-28-14Reiterated RBC Capital Mkts Outperform $151 → $158
Feb-27-14Reiterated Aegis Capital Buy $160 → $180
Jan-08-14Reiterated UBS Buy $125 → $141
Jan-08-14Reiterated Ladenburg Thalmann Buy $123 → $155
Jan-08-14Reiterated FBR Capital Outperform $130 → $153
Dec-03-13Reiterated UBS Buy $115 → $125
Nov-01-13Reiterated Ladenburg Thalmann Buy $127 → $123
Oct-30-13Initiated FBR Capital Outperform $130
May-26-15 04:25PM  Pharmacyclics' Imbruvica Gets CHMP's Nod for Full Approval - Analyst Blog
03:12PM  5 most popular health-care stocks among hedge funds at MarketWatch
11:39AM  5 Most Popular Healthcare Stocks Among Hedge Funds at Insider Monkey
08:02AM  5 Drugs That Could Be Summer Blockbusters at Investor's Business Daily
12:26AM  Overheard: Bubble Talk Wont Slow Health Care Merger Pace at The Wall Street Journal
May-25-15 07:48PM  Overheard at The Wall Street Journal
06:02PM  'Bubble' Talk Won't Slow Health Care Merger Pace at The Wall Street Journal
02:00PM  Bristol-Myers' Opdivo Gets Positive Opinion from CHMP - Analyst Blog
01:00AM  Pharming and Cytobioteck Announce Distribution Agreement for Ruconest PR Newswire
May-23-15 01:36PM  VIDEO: 10 Growth Stocks in 10 Minutes
May-22-15 05:10PM  The 5 Most Controversial Trades Of 2015 From Ackman To Gross And Gundlach at Forbes
01:10PM  The 5 Most Controversial Trades Of 2015 From Ackman To Gross And Gundlach
12:28PM  5 Investments That Show John Paulson Knows How to Play M&A at TheStreet
10:34AM  Valeant CEO: Healthcare Sector A 'Bit Of A Bubble'
09:00AM  A Look at the Canadian Economy, Stock ETFs
08:51AM  Calithera Biosciences (CALA) in Focus, Stock Rises 10.8% - Tale of the Tape
May-21-15 06:03PM  Valeant's Pearson: Health-Care M&A, Acquisition Strategy at Bloomberg
05:03PM  Hedge Funds Keep Betting Big On Health Care at Forbes
04:53PM  Valeant CEO Pearson Sees Bit of a Bubble in Health-Care M&A at Bloomberg
03:02PM  Retail And Oil Stocks Outperform In Quiet Session at Investor's Business Daily
02:33PM  Billionaire Stephen Mandels Top Picks: Priceline Group Inc (PCLN), JD.Com Inc (ADR) (JD), Mastercard Inc (MA) & Valeant Pharmaceuticals Intl Inc (VRX) at Insider Monkey
01:00PM  50 stocks that matter most to hedge-fund Masters of the Universe at MarketWatch
11:58AM  Alibaba, Dollar General and 3 Other Stocks Big Hedge Funds Hated Last Quarter at TheStreet
09:49AM  5 Stocks the Biggest Hedge Funds Bought Last Quarter at TheStreet
12:00AM  Health Care Stocks Prove Canadas Best Catching U.S. at Bloomberg
May-20-15 11:38AM  Billionaire Ackman Loves Valeant Pharmaceuticals Intl Inc (VRX), Air Products & Chemicals Inc. (APD), Canadian Pacific Railway Limited (USA)(CP) at Insider Monkey
07:03AM  Valeant in talks to buy Egyptian drugmaker Amoun Pharma-Bloomberg
06:07AM  Valeant Said to Be in Talks to Acquire Egyptian Drugmaker Amoun at Bloomberg
May-19-15 05:00PM  Valeant Pharmaceuticals Announces 2015 Annual Meeting Results PR Newswire
05:00PM  Valeant Pharmaceuticals Announces 2015 Annual Meeting Results CNW Group
04:59PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
03:16PM  Medtronic PLC (MDT), Actavis plc (ACT): Zweig-DiMenna Partners Top Picks from Healthcare Sector at Insider Monkey
02:00PM  Lannett (LCI) Signs Deal to Acquire Silarx Pharmaceuticals - Analyst Blog
01:59PM  Nasdaq couldnt be better for intermediate-term speculators at MarketWatch
01:04PM  Valeant CEO expects sharp rise in Asia revenue by 2020
06:23AM  ECB peps markets and JPMorgan shareholders vote on Dimons pay5 things to know today at Fortune
May-18-15 04:54PM  Endo Vaults Into Top 5 Among Generic-Drug Firms
04:54PM  Endo Buying Par Pharma To Become Top Generics Player at Investor's Business Daily
04:02PM  Hedge funds are beating the S&P 500; here's how at CNBC
10:06AM  Healthcare AM Winners and Losers: May 18, 2015
09:35AM  Jeffrey Ubben Has a Surprise Entry Among His Top Stock Picks at Insider Monkey
09:01AM  The Symmetric Top Twenty: heres what the best of the best are doing in the market
08:58AM  More Waves In Pharma: Endo Buys TPG Capital's Par Pharma for $8 Billion
08:33AM  The pharma M&A party is still in full swing, as Endo snaps up Par at Fortune
08:02AM  Endo to buy Par from TPG Capital in in $8bn deal at Financial Times
01:00AM  Pharming and Clinigen Group Initiate "HAEi GAP" Global Access Program for RUCONEST® PR Newswire
May-16-15 09:54AM  Bill Ackman's Latest Moves In Health Care & Some Other Positions From Q1
May-15-15 05:51PM  Ackman's Pershing Square Slashes Stake in Combined the Allergan/Actavis at The Wall Street Journal
05:31PM  Paulson Increased Stake in Valeant During First Quarter at The Wall Street Journal
04:45PM  Big name investors take sides on Ackman bet on Valeant: filings Reuters
03:25PM  Corcept Therapeutics' Korlym Positive in Breast Cancer Study - Analyst Blog
01:40PM  Eli Lilly, Sanford-Burnham Ink Deal for Immunotherapies - Analyst Blog
May-14-15 06:46PM  Locust Wood Capital Bet on Top Performer Valeant Pharmaceuticals
11:32AM  Looking for Investment Ideas? These Wall Street Heavyweights Just Gave You a Bunch at TheStreet
May-13-15 11:37AM  Ex-Goldman Banker Channels Loeb to Give Tiny Firm Heft at Bloomberg
May-12-15 07:00PM  Ex-Goldman Banker Channels Dan Loeb to Give Clout to a Tiny Firm
04:05PM  Valeant Pharmaceuticals To Webcast 2015 Annual Meeting Of Shareholders PR Newswire
04:05PM  Valeant Pharmaceuticals To Webcast 2015 Annual Meeting Of Shareholders CNW Group
11:03AM  Canada Stocks Decline in Global Equities Slide; Air Canada Gains at Bloomberg
09:38AM  Investing Like Ackman Lifts Canada Index as Valeant Gains at Bloomberg
06:20AM  Value Stocks Are Getting a Lot Harder for Investors to Find at TheStreet
May-11-15 04:50PM  Novartis' Zykadia Approved in the EU for Lung Cancer - Analyst Blog
01:42PM  Sealed Air Corp. (SEE), Grace (W.R.) & Co. (GRA): Iridian Asset Management Discloses 13F Portfolio for Q2 at Insider Monkey
May-10-15 11:39AM  VIDEO: Stocks Showing Great Relative Strength
May-09-15 12:01AM  Valeant vs. Buffett at Barrons.com
May-08-15 01:00PM  Corcept Therapeutics Reports Wider Q1 Loss, Revenue Miss - Analyst Blog
11:20AM  ARIAD (ARIA) Q1 Loss Wider than Estimates; Iclusig Grows - Analyst Blog
May-07-15 12:54PM  JPMorgan: Buy Actavis, Bristol Myers, Valeant at Barrons.com
May-06-15 01:04PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Financials
06:53AM  Baby Buffett: Will Bill Ackman Resurrect The Ghost Of Howard Hughes And Build A Corporate Empire? at Forbes
May-05-15 02:35PM  Jarden Up 5% on Ackman's Comments at Ira Sohn Conference - Analyst Blog
May-04-15 08:12PM  10-Q for Valeant Pharmaceuticals International, Inc. at Company Spotlight
07:29PM  Bill Ackman: Valeant is the next Berkshire Hathaway at Fortune
07:29PM  Bill Ackman: Valeant could be the next Berkshire Hathaway at Fortune
06:41PM  Live From Sohn: Valeant is Just Like Berkshire Hathaway, Bill Ackman Says at Barrons.com
06:27PM  Einhorn targets US 'frack addicts' at Financial Times
06:22PM  Bill Ackman Describes Valeant as Early Stage Berkshire Hathaway at Bloomberg
09:01AM  Hedge Funds Gained the Most from these Five Stocks Last Week
May-02-15 12:01AM  The Barron's 500 at Barrons.com
May-01-15 04:08PM  Are Drug Mergers In Their Final Act?
03:40PM  Biotech's torrid run may not be over, analyst says at CNBC
02:09PM  Biotech's big outlook
12:15PM  Viking Global's Shareholder Letter Talks New Positions In Google, Cheniere, Biggest Winners & Losers
10:31AM  Canadian Stocks Rise as Valeant, Base Metals Producers Advance at Bloomberg
09:09AM  Valeant Pharmaceuticals Reports In-Line Earnings, Ups View - Analyst Blog
Apr-30-15 03:43PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 10-Q, Quarterly Report
01:57PM  Barclays Calls Valeant Its Top Pick at The Wall Street Journal
12:32PM  Pharming Reports on Annual General Meeting of Shareholders PR Newswire
11:14AM  Canada Stocks Slide as Gold Declines Overshadow Valeant Rally at Bloomberg
09:54AM  Stifel Raises Valeant PT As Co. Continues To Execute Global Expansion Strategy
03:56AM  Valeant Pharmaceuticals (VRX) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
01:00AM  Pharming Reports on Financial Results for Q1 2015 PR Newswire
Apr-29-15 05:13PM  Valeant Beats Q1 Views, Lifts Guidance, Loses CFO at Investor's Business Daily
01:57PM  Valeant raises outlook after completing purchase of Salix
01:22PM  Indexes Lower, Near Session Lows As Fed Announcement Nears at Investor's Business Daily
01:02PM  Valeant Pharmaceuticals: Scoreboard watching at Financial Times
10:55AM  Valeant Beats Q1 Views, Lifts Guidance, But Loses CFO at Investor's Business Daily
10:24AM  Drugmaker Valeant raises forecasts, says CFO to leave
09:45AM  Express Scripts Posts In-line Q1 Earnings, Revenues Beat - Analyst Blog
09:15AM  Morgan Stanley Reviews Valeant Pharmaceuticals' Earnings
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer. It also provides Zovirax, an antiviral for recurrent herpes labialis and initial genital herpes; Syprine to treat patients with Wilson's disease; Elidel to treat atopic dermatitis; Prolensa for inflammation and pain following cataract surgery; Duromine, a weight loss drug; and Lotemax gel for post-operative inflammation and pain. In addition, the company offers PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; ReNu Multiplus to lubricate and rewet soft contact lenses; Biotrue for healthy contact lens wear; Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; AntiGrippin for acute respiratory and respiratory viral diseases, and influenza; and Bedoyecta, a vitamin B complex product. Further, it provides SofLens daily disposable contact lenses; PureVision, a contact lens; various ophthalmic surgical products; Biotrue ONEday lens; medical device systems for aesthetic applications; and Bausch + Lomb Ultra, a contact lens. Additionally, the company offers Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Cardizem CD to treat hypertension and angina; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chai-Onn Robert RoswellEVP, CLO, General CounselMay 05Option Exercise6.1021,807133,02364,994May 06 05:51 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMay 04Option Exercise25.4290,9382,311,644134,125May 06 05:51 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMay 04Sale222.5490,93820,237,44343,187May 06 05:51 PM
Kornwasser LaizerEVP, Company Group ChairmanApr 17Option Exercise0.0045,0000123,377Apr 21 05:46 PM
Mirovsky PavelPresident, EMENAApr 15Option Exercise0.0024,175034,175Apr 17 05:28 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMar 03Option Exercise6.1021,808133,02943,187Mar 04 05:24 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMar 02Option Exercise25.4290,9392,311,669112,296Mar 04 05:24 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMar 02Sale200.0190,93918,189,09121,379Mar 04 05:24 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMEAFeb 27Option Exercise0.0010,000010,000Mar 02 05:16 PM
Stolz Brian M.EVP, Administration and CHCOJan 22Option Exercise0.007,350095,934Jan 26 05:22 PM
Schiller Howard BradleyEVP, Chief Financial OfficerJan 05Option Exercise0.0045,0000318,714Jan 07 05:38 PM
Stolz Brian M.EVP, CHCO and AdministrationDec 23Option Exercise0.0015,426096,618Dec 24 10:31 AM
Farmer Ronald HaroldDirectorDec 12Buy160.4850080,24033,004Dec 16 02:59 PM
UBBEN JEFFREY WDirectorDec 10Buy139.2950,0006,964,50018,030,936Dec 11 06:59 PM
UBBEN JEFFREY WDirectorDec 09Buy140.25200,00028,050,00017,980,936Dec 11 06:59 PM
STEVENSON KATHARINE BERGHUISDirectorDec 03Buy145.731,500218,59523,098Dec 03 04:48 PM
Farmer Ronald HaroldDirectorNov 24Buy163.951,000163,95032,504Dec 01 05:25 PM
UBBEN JEFFREY WDirectorNov 24Buy142.25210,00029,872,50017,780,936Nov 26 04:11 PM
Stolz Brian M.EVP, Administration and CHCOOct 10Option Exercise0.003,675084,791Oct 14 02:51 PM
Schiller Howard BradleyEVP and CFOOct 03Option Exercise0.0022,5000285,500Oct 07 04:19 PM
Stolz Brian M.EVP, Administration and CHCOSep 30Option Exercise0.0023,030093,064Oct 02 03:52 PM
Stolz Brian M.EVP, CHCO and AdministrationAug 06Option Exercise0.0018,111079,431Aug 07 03:53 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Jun 23Option Exercise6.4510,20365,80934,202Jun 24 04:37 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Jun 23Sale121.7010,2031,241,67623,999Jun 24 04:37 PM
Mirovsky PavelPresident of Valeant EuropeJun 02Sale131.2510,0001,312,4860Jun 04 03:19 PM